Infusion reactions: Diagnosis, assessment, and management

Clinical Journal of Oncology Nursing

Volumn 14, Issue 2, 2010, Pages

  Vogel, Wendy H ^a  

^a Kingsport Hematology Oncology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG HYPERSENSITIVITY; HUMAN; IMMUNE SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASM; NURSING ASSESSMENT; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG HYPERSENSITIVITY; HUMANS; IMMUNE SYSTEM; INFUSIONS, INTRAVENOUS; NEOPLASMS; NURSING ASSESSMENT;

EID: 77955297314     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.E10-E21     Document Type: Article

References (60)

1. Amgen Inc. (2008). Vectibix® (panitumumab) [Package insert]. Thousand Oaks, CA: Author.
2. Bello, C., & Sotomayor, E.M. (2007). Monoclonal antibodies for B-cell lymphomas: Rituximab and beyond. Hematology, 2007, 233-242. doi: 10.1182/asheducation-2007.1.233
3. Berlex Laboratories. (2001). Campath® (alemtuzumab) [Package insert]. Richmond, CA: Author.
4. Breslin, S. (2007). Cytokine-release syndrome: Overview and nursing implications. Clinical Journal of Oncology Nursing, 11(1, Suppl.), 37-42. doi: 10.1188/07.CJON.S1.37-42
5. Bristol-Myers Squibb. (2007a). Paraplatin® (carboplatin aqueous solution) injection [Package insert]. Princeton, NJ: Author.
6. Bristol-Myers Squibb. (2007b). Taxol® (paclitaxel) injection [Package insert]. Princeton, NJ: Author.
7. Bristol-Myers Squibb. (2009). Erbitux® (cetuximab) solution for intravenous injection [Package insert]. Princeton, NJ: Author.
8. Brown, S.G., Mullins, R.J., & Gold, M.S. (2006). Anaphylaxis: Diagnosis and management. Medical Journal of Australia, 185, 283-289.
9. Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., Flinn, I.W. (2001). Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and smalllymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology, 19, 2153-2164.
10. Byrd, J.C., Waselenko, J.K., Maneatis, T.J., Murphy, T., Ward, F.T., Monahan, B.P., White, C.A. (1999). Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. Journal of Clinical Oncology, 17, 791-795.
11. Chung, C.H. (2008). Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist, 13, 725-732. doi: 10.1634/theoncologist.2008-0012
12. Coiffier, B., Feugier, P., Mounier, N., Franchi-Rezgui, P., Van Den Neste, E., Macro, M., Tilly, H. (2007). Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients [Abstract 8009]. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=30903
13. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R.,.Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-Bcell lymphoma. New England Journal of Medicine, 346, 235-242. doi: 10.1056/NEJMoa011795
14. Davis, T.A., Grillo-Lopez, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., Levy, R. (2000). Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. Journal of Clinical Oncology, 18, 3135-3143.
15. Davis, T.A., White, C.A., Grillo-Lopez, A.J., Velasquez, W.S., Link, B., Maloney, D.G., Levy, R. (1999). Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. Journal of Clinical Oncology, 17, 1851-1857.
16. Dillman, R.O., & Hendrix, C.S. (2003). Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Supportive Cancer Therapy, 1, 38-48. doi: 10.3816/SCT.2003.n.003
17. Edwards, J.C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D.R., Shaw, T. (2004). Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine, 350, 2572-2581. doi: 10.1056/NEJMoa032534
18. Genentech, Inc. (2008). Avastin® (bevacizumab) [Package insert]. San Francisco, CA: Author.
19. Genentech, Inc. (2009). Herceptin® (trastuzumab) [Package insert]. San Francisco, CA: Author.
20. Genentech, Inc. (2010). Rituxan® (rituximab) [Package insert]. San Francisco, CA: Author.
21. Gobel, B.H. (2005). Chemotherapy-induced hypersensitivity reactions. Oncology Nursing Forum, 32, 1027-1035. doi: 10.1188/04.ONF.1027-1035
22. Hallek, M., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M. Fischer, K. (2008). Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [Abstract]. Blood, 112, 125.
23. Johnson, P., & Glennie, M. (2003). The mechanisms of action of rituximab in the elimination of tumor cells. Seminars in Oncology, 30(1, Suppl. 2), 3-8. doi: 10.1053/sonc.2003.50025
24. Kang, S.P., & Saif, M.W. (2007). Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer-Identification, prevention, and management. Journal of Supportive Oncology, 5, 451-457.
25. Kemp, S.F., Lockey, R.F., & Simons, F.E. (2008). Epinephrine: The drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy, 63, 1061-1070. doi: 10.1111/j.1398-9995.2008.01733.x
26. Kimby, E. (2005). Tolerability and safety of rituximab (MabThera). Cancer Treatment Reviews, 31, 456-473. doi: 10.1016/j.ctrv.2005.05.007
27. Kohler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-497.
28. Lenz, H.J. (2007). Management and preparedness for infusion and hypersensitivity reactions. Oncologist, 12, 601-609. doi: 10.1634/ theoncologist.12-5-601
29. Li, H., Ayer, L.M., Lytton, J., & Deans, J.P. (2003). Store-operated medication entry mediated by CD20 in membrane rafts. Journal of Biological Chemistry, 278, 42427-42434.
30. Lieberman, P., Kemp, S.F., Oppenheimer, J., Lang, D.M., Bernstein, I.L., Nicklas, R.A., Fink, J. (2005). The diagnosis and management of anaphylaxis: An updated practice parameter. Journal of Allergy and Clinical Immunology, 115(3, Suppl. 2), S483-S523. doi: 10.1016/j.jaci.2005.01.010
31. Maloney, D.G., Grillo-Lopez, A.J., Bodkin, D.J., White, C.A., Liles, T.M., Royston, I., Levy, R. (1997). IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology, 15, 3266-3274.
32. Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Levy, R. (1997). IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, 2188-2195.
33. Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994). Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84, 2457-2466.
34. Maloney, D.G., Smith, B., & Appelbaum, F.R. (1996). The antitumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood, 88, 637.
35. Mathas, S., Rickers, A., Bommert, K., Dorken, B., & Mapara, M.Y. (2000). Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways. Cancer Research, 60, 7170-7176.
36. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., & Dallaire, B.K. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
37. National Cancer Institute. (2006). Common Terminology Criteria for Adverse Events [v3.0]. Retrieved from http://ctep.cancer.gov/protocol Development/electronic_applications/docs/ctcaev3.pdf
38. O'Brien, S.M., Kantarjian, H., Thomas, D.A., Giles, F.J., Freireich, E.J., Cortes, J., Keating, M.J. (2001). Rituximab dose-escalation trial in chronic lymphocytic leukemia. Journal of Clinical Oncology,19, 2165-2170.
39. Oldham, R.K., & Dillman, R.O. (2008). Monoclonal antibodies in cancer therapy: 25 years of progress. Journal of Clinical Oncology,26, 1774-1777.
40. O'Neil, B.H., Allen, R., Spigel, D.R., Stinchcombe, T.E., Moore, D.T., Berlin, J.D., & Goldberg, R.M. (2007). High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. Journal of Clinical Oncology,25, 3644-3648.
41. Osterborg, A., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmen, A., Wierda, W.G. (2008). Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trial [Abstract]. Blood, 112, 126.
42. Peereboom, D.M., Donehower, R.C., Eisenhauer, E.A., McGuire, W.P., Onetto, N., Hubbard, J.L., Rowinsky, E.K. (1993). Successful retreatment with taxol after major hypersensitivity reactions. Journal of Clinical Oncology, 11, 885-890.
43. Piro, L.D., White, C.A., Grillo-Lopez, A.J., Janakiraman, N., Saven, A., Beck, T.M., Jain, V. (1999). Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology, 10,655-661.
44. Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Anderson, D.R. (1994). Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood,83, 435-445.
45. Rieger, P.T. (2001). Biotherapy: An overview. In P.T. Rieger (Ed.), Biotherapy: A comprehensive review (pp. 3-37). Sudbury, MA: Jones and Bartlett.
46. Riley, J.K., & Sliwkowski, M.X. (2000). CD20: A gene in search of a function. Seminars in Oncology, 27(6, Suppl. 12), 17-24.
47. Saif, M.W. (2006). Hypersensitivity reactions associated with oxaliplatin. Expert Opinion on Drug Safety, 5, 687-694. doi: 10.1517/14740338.5.5.687
48. Salar, A., Casao, D., Cervera, M., Pedro, C., Calafell, M., Abella, E., Besses, C. (2006). Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. European Journal of Haematology, 77, 338-340. doi: 10.1111/j.1600-0609.2006.00713.x
49. sanofi-aventis U.S. LLC. (2008). Taxotere® (docetaxel) injection concentrate [Package insert]. Bridgewater, NJ: Author.
50. sanofi-aventis U.S. LLC. (2009). Eloxatin® (oxaliplatin powder for solution) [Package insert]. Bridgewater, NJ: Author.
51. Schulz, H., Bohlius, J.F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Engert, A. (2007). Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. Journal of the National Cancer Institute, 99, 706-714. doi: 10.1093/jnci/djk152
52. Sehn, L.H., Donaldson, J., Filewich, A., Fitzgerald, C., Gill, K.K., Runzer, N., Connors, J.M. (2007). Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood, 109, 4171-4173.
53. Shan, D., Ledbetter, J.A., & Press, O.W. (2000). Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunology, Immunotherapy, 48, 673-683.
54. Siano, M., Lerch, E., Negretti, L., Zucca, E., Rodriguez-Abreu, D., Oberson, M., Ghielmini, M. (2008). A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clinical Cancer Research, 14, 7935-7939. doi: 10.1158/1078 -0432.CCR-08-1124
55. Sliesoraitis, S., & Chikhale, P.J. (2005). Carboplatin hypersensitivity. International Journal of Gynecological Cancer, 15, 13-18.
56. Solomon, S., & Komanduri, K. (2001). The immune system. In P.T. Rieger (Ed.), Biotherapy: A comprehensive review (pp. 39-63).
57. Sudbury, MA: Jones and Bartlett. Tam, C.S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.A., Keating, M.J. (2008). Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood, 112, 975-980. doi: 10.1182/ blood-2008-02-140582
58. Vial, T., & Descotes, J. (1995). Immune-mediated side-effects of cytokines in humans. Toxicology, 105, 31-57.
59. Weiss, R.B. (1992). Hypersensitivity reactions. Seminars in Oncology, 19, 458-477.
60. Zanotti, K.M., & Markman, M. (2001). Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety, 24, 767-779.